Bortezomib Combination Therapy in Multiple Myeloma

Seminars in Hematology

Volumn 49, Issue 3, 2012, Pages 228-242

  Kapoor, Prashant ^a   Ramakrishnan, Vijay ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BELINOSTAT; BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; ETOPOSIDE; IMMUNOMODULATING AGENT; INTERFERON; LENALIDOMIDE; LONAFARNIB; MAPATUMUMAB; MELPHALAN; OBATOCLAX; PANOBINOSTAT; PERIFOSINE; POMALIDOMIDE; PREDNISONE; PROTEASOME; ROMIDEPSIN; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UBIQUITIN; UNINDEXED DRUG; VORINOSTAT;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CYTOPENIA; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; INFUSION RELATED REACTION; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84862696482     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.04.010     Document Type: Article

References (69)

1. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639.
2. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
3. Kumar S.K., Lee J.H., Lahuerta J.J., et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012, 26:149-157.
4. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
5. Richardson P.G., Barlogie B., Berenson J., et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006, 106:1316-1319.
6. Jagannath S., Barlogie B., Berenson J.R., et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008, 143:537-540.
7. Richardson P.G., Sonneveld P., Schuster M., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110:3557-3560.
8. Ling S.C., Lau E.K., Al-Shabeeb A., et al. Response of myeloma to proteasome inhibitor bortezomib is correlated with unfolded protein response regulator XBP-1. Haematologica 2012 Jan, 97:64-72.
9. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
10. Anderson K.C., Jagannath S., Jakubowiak A., et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study. ASCO Meeting Abstracts 2009, 27(15S):8536.
11. Kumar S., Flinn I.W., Richardson P.G., et al. Randomized, multicenter phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide and lenalidomide in previously untreated multiple myeloma. Blood 2012 Mar 17, Epub ahead of print.
12. Cavo M., Tacchetti P., Patriarca F., et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010, 376:2075-2085.
13. Rosinol L., Cibeira M.T., Martinez J., et al. Thalidomide/dexamethasone (TD) vs. bortezomib (Velcade)a/thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcadea as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA/GEM trial. ASH Annual Meeting Abstracts 2009, 114:130.
14. Moreau P., Avet-Loiseau H., Facon T., et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011, 118:5752-5758.
15. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101:2377-2380.
16. San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359:906-917.
17. Miguel J.F.S., Schlag R., Khuageva N.K., et al. Continued overall survival benefit after 5 years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 VISTA trial. ASH Annual Meeting Abstracts 2011, 118(21):476.
18. Miguel J.F.S., Richardson P.G., Orlowski R.Z., et al. Risk of second primary malignancies (SPMs) following bortezomib (Btz)-based therapy: analysis of four phase 3 randomized controlled trials in previously untreated or relapsed multiple myeloma (MM). ASH Annual Meeting Abstracts 2011, 118:2933.
19. Mateos M.V., Oriol A., Martinez-Lopez J., et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010, 11:934-941.
20. Palumbo A., Bringhen S., Rossi D., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, 28:5101-5109.
21. Moreau P., Pylypenko H., Grosicki S., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12:431-440.
22. Niesvizky R., Flinn I.W., Rifkin R., et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. ASH Annual Meeting Abstracts 2011, 118:478.
23. Niesvizky R., Flinn I.W., Rifkin R., et al. Patient-reported quality of life (QoL) in elderly, newly diagnosed multiple myeloma (MM) patients receiving bortezomib-based combinations: results from all randomized patients in the community-based, phase 3b UPFRONT study. ASH Annual Meeting Abstracts 2011, 118:1864.
24. Reeder C.B., Reece D.E., Kukreti V., et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009, 23:1337-1341.
25. Reeder C.B., Reece D.E., Kukreti V., et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010, 115:3416-3417.
26. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25:3892-3901.
27. Ciolli S., Leoni F., Casini C., Breschi C., Santini V., Bosi A. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. Br J Haematol 2008, 141:814-819.
28. Berenson J.R., Yellin O., Chen C.S., et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol 2011, 155:580-587.
29. Jakubowiak A.J., Kendall T., Al-Zoubi A., et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009, 27:5015-5022.
30. Popat R., Oakervee H.E., Hallam S., et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008, 141:512-516.
31. Sonneveld P., Schmidt-Wolf I., van der Holt B., et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 2010, 116:40.
32. Sonneveld P., van der Holt B., Schmidt-Wolf I.G.H., et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III Trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts 2008, 112:653.
33. Neben K., Lokhorst H.M., Jauch A., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012, 119:940-948.
34. Pineda-Roman M., Zangari M., Haessler J., et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008, 140:625-634.
35. Hoering A., Mitchell A., Sexton R., Crowley J., Barlogie B. Prognostic index for predicting overall survival and event-free survival in Total Therapy 3 patients. ASH Annual Meeting Abstracts 2010, 116:1342.
36. Nair B., van Rhee F., Shaughnessy J.D., et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010, 115:4168-4173.
37. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006, 107:1092-1100.
38. Richardson P.G., Chanan-Khan A.A., Lonial S., et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol 2011, 153:729-740.
39. Richardson P.G., Badros A.Z., Jagannath S., et al. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010, 150:428-437.
40. McConkey D. Proteasome and HDAC: who's zooming who?. Blood 2010, 116:308-309.
41. Richardson P.G., Alsina M., Weber D.M., et al. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). ASH Annual Meeting Abstracts 2011, 118:814.
42. Harrison S.J., Quach H., Link E., et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011, 118:6274-6283.
43. Siegel D., Bilotti E., McBride L., et al. Vorinostat overcomes resistance in patients with multiple myeloma refractory to bortezomib, lenalidonide and dexamethasone. Hematologica 2011, 96(s1):S94.
44. Dimopoulos M.A., Jagannath S., Yoon S.-S., et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. ASH Annual Meeting Abstracts 2011, 118:811.
45. San-Miguel J.F., de Moraes Hungria V.T., Yoon S.-S., et al. Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1. ASH Annual Meeting Abstracts 2011, 118:3976.
46. Hidalgo M. From node to pathway blockade: lessons learned from targeting mammalian target of rapamycin. J Clin Oncol 2012, 30:85-87.
47. Maiso P., Liu Y., Morgan B., et al. Defining the role of TORC1/2 in multiple myeloma. Blood 2011, 118:6860-6870.
48. Ghobrial I.M., Weller E., Vij R., et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011, 12:263-272.
49. Hideshima T., Catley L., Yasui H., et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006, 107:4053-4062.
50. Richardson P.G., Wolf J., Jakubowiak A., et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 2011, 29:4243-4249.
51. Alsina M., Fonseca R., Wilson E.F., et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004, 103:3271-3277.
52. Lonial S., Francis D., Karanes C., et al. A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 2008, 112:3706.
53. Richardson P.G., Lonial S., Jakubowiak A.J., Harousseau J.L., Anderson K.C. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2011, 154:745-754.
54. Belch A., Sharma A., Spencer A., et al. A multicenter randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with bortezomib in patients with relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 2010, 116:5031.
55. Jakubowiak A.J., Benson D.M., Bensinger W., et al. Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: updated results of a phase I study. ASH Annual Meeting Abstracts 2010, 116:3023.
56. Kumar S.K., Flinn I., Noga S.J., et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase I results from the multicenter EVOLUTION study. Leukemia 2010, 24:1350-1356.
57. Jakubowiak A.J., Griffith K.A., Reece D.E., et al. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 2011, 118:535-543.
58. Kropff M., Liebisch P., Knop S., et al. DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Ann Hematol 2009, 88:1125-1130.
59. Sher T., Ailawadhi S., Miller K.C., et al. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol 2011, 154:104-110.
60. Belch A., Reece D.E., Bahlis N.J., et al. Bortezomib [VELCADE], pegylated liposomal doxorubicin [DOXIL/CAELYX] and dexamethasone in the treatment of previously untreated multiple myeloma patients: impact on quality-of-life. ASH Annual Meeting Abstracts 2007, 110:3618.
61. Reece D.E., Rodriguez G.P., Chen C., et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008, 26:4777-4783.
62. Kropff M., Bisping G., Schuck E., et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007, 138:330-337.
63. Palumbo A., Gay F., Bringhen S., et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 2008, 19:1160-1165.
64. Berenson J.R., Yellin O., Bessudo A., et al. Bendamustine combined with bortezomib has efficacy in patients with relapsed or refractory multiple myeloma: a phase 1/2 study. ASH Annual Meeting Abstracts 2011, 118:1857.
65. Siegel D.S., Dimopoulos M.A., Yoon S.-S., et al. Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. ASH Annual Meeting Abstracts 2011, 118:480.
66. Ghobrial I.M., Munshi N.C., Harris B.N., et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011, 86:573-578.
67. Rossi J.-F., Manges R.F., Sutherland H.J., et al. Preliminary Results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 2008, 112:867.
68. Rosinol L., Cibeira M.T., Mateos M.V., et al. Results of pre- and post- autologous stem cell transplantation (ASCT) with three induction regimens in multiple myeloma (MM): superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib (VBMCP/VBAD/V). Hematologica 2011, 96(S1):S69.
69. Garderet L., Iacobelli S., Moreau P., et al. Bortezomib (Velcade)-thalidomide-dexaemthasone (VTD) is superior to thalidomide-dexaemthasone (TD) in patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation. Hematologica 2011, 96(s1):S72-S73.